Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD

Inclusion Criteria: * Physician-diagnosed COPD * Initiated treatment with BGF MDI as prescribed according to the summary of product characteristics (SmPC) and local market reimbursement criteria; * Patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol * After full explanation, patients must have signed an informed consent document indicating that they understand the purpose of, and the procedures required for the study and are willing to participate in the study Exclusion Criteria: * COPD due to known α-1 antitrypsin deficiency * Previous treatment with triple fixed-dose combination in 12 months prior to baseline * Hospitalization due to COPD exacerbation within the last 30 days prior to index date * Pregnancy or lactation period * Other uncontrolled disease, that might, in the investigator's opinion, influence the assessment for the current study * Participation in a non-interventional, observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in any interventional clinical trial in the last 30 days prior to baseline. * Hospitalization for Covid-19 infection in the last 30 days prior to index date